Arbutus Biopharma
ABUS
ABUS
118 hedge funds and large institutions have $131M invested in Arbutus Biopharma in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 39 increasing their positions, 35 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
15% less capital invested
Capital invested by funds: $154M → $131M (-$23M)
15% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 20
18% less call options, than puts
Call options by funds: $5.7M | Put options by funds: $6.99M
Holders
118
Holding in Top 10
2
Calls
$5.7M
Puts
$6.99M
Top Buyers
| 1 | +$7.98M | |
| 2 | +$6.06M | |
| 3 | +$4.09M | |
| 4 |
BC
Brookfield Corp
Toronto,
Ontario, Canada
|
+$3.38M |
| 5 |
Goldman Sachs
New York
|
+$2.53M |
Top Sellers
| 1 | -$9.74M | |
| 2 | -$3.05M | |
| 3 | -$2.6M | |
| 4 |
Two Sigma Investments
New York
|
-$2.28M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.97M |